<DOC>
	<DOC>NCT01870986</DOC>
	<brief_summary>This healthy volunteers study will evaluate 210 subjects who will receive a single sub-cutaneous dose of PF-06410293 or adalimumab (United States) or adalimumab (European Union). This study will involve sampling and pharmacokinetics evaluation of drug levels following administration of PF-06410293 and the licensed adalimumab products.</brief_summary>
	<brief_title>Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)</brief_title>
	<detailed_description />
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Healthy male and female (nonchildbearing potential). Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination including blood pressure, pulse, ECG, and laboratory testing. Evidence or history of clinically significant infectious, hematological, renal, endocrine, pulmonary gastrointestinal, cardiovascular, hepatic psychiatric, neurologic, autoimmune, or allergic disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Phase 1</keyword>
	<keyword>PK</keyword>
	<keyword>adalimumab</keyword>
	<keyword>Single-dose</keyword>
	<keyword>Immunology</keyword>
	<keyword>Bioequivalence</keyword>
	<keyword>Biosimilarity</keyword>
	<keyword>Similarity.</keyword>
</DOC>